Media headlines about Mylan (NASDAQ:MYL) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mylan earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.5363954298707 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Key Risks Facing Mylan in January 2018 – Market Realist (marketrealist.com)
- How Mylan’s Europe Segment Performed in 3Q17 – Market Realist – Market Realist (marketrealist.com)
- Recent Developments for Mylan – Market Realist (marketrealist.com)
- Nestle takes the lead over Mylan, Reckitt in Merck KGaA’s $4B-plus OTC sale: report – FiercePharma (fiercepharma.com)
- Goldman rates Mylan tops in generic drug space, sees 14% upside … – Seeking Alpha (seekingalpha.com)
A number of research analysts have weighed in on the stock. Goldman Sachs Group boosted their price objective on shares of Mylan from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday. Zacks Investment Research cut shares of Mylan from a “hold” rating to a “sell” rating in a report on Tuesday. Citigroup restated a “buy” rating and issued a $58.00 price target (up from $48.00) on shares of Mylan in a report on Thursday, January 4th. Leerink Swann initiated coverage on shares of Mylan in a report on Tuesday, January 2nd. They issued a “market perform” rating and a $44.00 price target on the stock. Finally, Cantor Fitzgerald set a $41.00 price target on shares of Mylan and gave the stock a “hold” rating in a report on Tuesday, December 26th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $43.64.
Mylan (NASDAQ:MYL) last issued its earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter in the previous year, the company earned $1.38 earnings per share. The firm’s revenue was down 2.3% on a year-over-year basis. research analysts predict that Mylan will post 4.56 earnings per share for the current year.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.69% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/01/11/mylan-myl-earning-somewhat-favorable-press-coverage-report-finds.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
What are top analysts saying about Mylan? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan and related companies.